Australia's CSL to Lower Medicaid Prices Amid U.S. Expansion

By Stuart Condie

SYDNEY--Australia-based pharmaceutical company CSL said it agreed to lower the prices it charges Medicaid as it moves forward with a previously announced $1.5 billion move to increase U.S. production.

CSL, which produces plasma-derived therapies for conditions including bleeding disorders and immune deficiencies, on Tuesday said it entered an agreement with the U.S. Department of Health and Human Services to give Medicaid access to medicines at prices comparable to those in other developed countries.

CSL said it will similarly price any newly launched therapies for all payers in the U.S.

The ASX-listed company said it has also signed an onshoring agreement with the U.S. Department of Commerce.

The agreements provide greater certainty regarding exposure to U.S. drug pricing and some tariffs, CSL said.

In March, CSL said it would expand its Illinois manufacturing facility. At the time, it said it expected the expanded Kankakee facility to be operational by 2031.

On Tuesday, CSL said it did not anticipate any material financial impact from the new agreements in its current fiscal year, which began July 1.

Write to Stuart Condie at stuart.condie@wsj.com

(END) Dow Jones Newswires

August 31, 2026 19:00 ET (23:00 GMT)